A six-month trial of the antiepileptic drug topiramate (TOPAMAX, Ortho-McNeil Pharmaceutical, Inc) for the treatment of obesity has found the drug helped reduce body weight between 6 percent and 8 percent, the principal investigator announced.
Dr. George Bray, formerly executive director of the Pennington Biomedical Research Center, Baton Rouge, La., said weight loss continued at the six-month cut-off point. In contrast, he said, the two weight-loss drugs currently on the market, orlistat (Xenical, Roche) and sibutramine (Meridia, Abbott Laboratories) plateau between three and six months, he said.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!